Key Takeaway: Precision BioSciences has received approval in Hong Kong to expand its PBGENE-HBV Phase 1 ELIMINATE-B trial, marking a significant milestone as it is the first in vivo gene editing clinical trial for chronic hepatitis B in the region. This approval is the second clinical trial application for PBGENE-HBV in 2024, and the study is currently recruiting patients globally.
Price reaction · baseline $4.45 (2024-12-18T18:00:00.000Z) · hit during market hours · clean, no other DTIL news in the window
day 0 close · peak
-7.2%
day 1
+3.4%
day 3
+1.1%
Market Sentiment Analysis
POSITIVE FACTORS
First clinical trial application clearance for in vivo gene editing in Hong Kong.
Second CTA approval for PBGENE-HBV in 2024.
Global, multi-site study actively recruiting patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024 – ELIMINATE-B is a global, multi-site study now actively recruiting patients; expected to report
Frequently Asked Questions
What is the PBGENE-HBV trial?
The PBGENE-HBV trial is a Phase 1 clinical study for treating chronic hepatitis B using gene editing.
Where has the PBGENE-HBV trial been approved?
The trial has received approval in Hong Kong, marking a significant milestone.
What does the ELIMINATE-B study focus on?
The ELIMINATE-B study focuses on the treatment of chronic hepatitis B through gene editing.
Is the trial actively recruiting patients?
Yes, the ELIMINATE-B trial is currently actively recruiting patients globally.